IBDEI1XU ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30953,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30953,1,3,0)
;;=3^Type 1 DM w/ Diabetic Nephropathy
;;^UTILITY(U,$J,358.3,30953,1,4,0)
;;=4^E10.21
;;^UTILITY(U,$J,358.3,30953,2)
;;=^5002589
;;^UTILITY(U,$J,358.3,30954,0)
;;=E10.22^^123^1598^16
;;^UTILITY(U,$J,358.3,30954,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30954,1,3,0)
;;=3^Type 1 DM w/ Diabetic CKD
;;^UTILITY(U,$J,358.3,30954,1,4,0)
;;=4^E10.22
;;^UTILITY(U,$J,358.3,30954,2)
;;=^5002590
;;^UTILITY(U,$J,358.3,30955,0)
;;=D59.3^^123^1598^3
;;^UTILITY(U,$J,358.3,30955,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30955,1,3,0)
;;=3^Hemolytic-uremic syndrome
;;^UTILITY(U,$J,358.3,30955,1,4,0)
;;=4^D59.3
;;^UTILITY(U,$J,358.3,30955,2)
;;=^55823
;;^UTILITY(U,$J,358.3,30956,0)
;;=D69.0^^123^1598^4
;;^UTILITY(U,$J,358.3,30956,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30956,1,3,0)
;;=3^Henoch-Schoeniein Purpura
;;^UTILITY(U,$J,358.3,30956,1,4,0)
;;=4^D69.0
;;^UTILITY(U,$J,358.3,30956,2)
;;=^5002365
;;^UTILITY(U,$J,358.3,30957,0)
;;=M30.0^^123^1598^12
;;^UTILITY(U,$J,358.3,30957,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30957,1,3,0)
;;=3^Polyarteritis nodosa
;;^UTILITY(U,$J,358.3,30957,1,4,0)
;;=4^M30.0
;;^UTILITY(U,$J,358.3,30957,2)
;;=^5011738
;;^UTILITY(U,$J,358.3,30958,0)
;;=M31.0^^123^1598^5
;;^UTILITY(U,$J,358.3,30958,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30958,1,3,0)
;;=3^Hypersensitivity angiitis
;;^UTILITY(U,$J,358.3,30958,1,4,0)
;;=4^M31.0
;;^UTILITY(U,$J,358.3,30958,2)
;;=^60279
;;^UTILITY(U,$J,358.3,30959,0)
;;=M31.31^^123^1598^22
;;^UTILITY(U,$J,358.3,30959,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30959,1,3,0)
;;=3^Wegener's granulomatosis w/ renal involvement
;;^UTILITY(U,$J,358.3,30959,1,4,0)
;;=4^M31.31
;;^UTILITY(U,$J,358.3,30959,2)
;;=^5011745
;;^UTILITY(U,$J,358.3,30960,0)
;;=N28.89^^123^1598^6
;;^UTILITY(U,$J,358.3,30960,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30960,1,3,0)
;;=3^Kidney & Ureter Disorders,Oth Specified
;;^UTILITY(U,$J,358.3,30960,1,4,0)
;;=4^N28.89
;;^UTILITY(U,$J,358.3,30960,2)
;;=^88007
;;^UTILITY(U,$J,358.3,30961,0)
;;=E85.4^^123^1598^11
;;^UTILITY(U,$J,358.3,30961,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30961,1,3,0)
;;=3^Organ-limited amyloidosis
;;^UTILITY(U,$J,358.3,30961,1,4,0)
;;=4^E85.4
;;^UTILITY(U,$J,358.3,30961,2)
;;=^5003017
;;^UTILITY(U,$J,358.3,30962,0)
;;=M32.14^^123^1598^2
;;^UTILITY(U,$J,358.3,30962,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30962,1,3,0)
;;=3^Glomerular disease in systemic lupus erythematosus
;;^UTILITY(U,$J,358.3,30962,1,4,0)
;;=4^M32.14
;;^UTILITY(U,$J,358.3,30962,2)
;;=^5011757
;;^UTILITY(U,$J,358.3,30963,0)
;;=M32.15^^123^1598^15
;;^UTILITY(U,$J,358.3,30963,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30963,1,3,0)
;;=3^Tubulo-interstitial neuropathy in SLE
;;^UTILITY(U,$J,358.3,30963,1,4,0)
;;=4^M32.15
;;^UTILITY(U,$J,358.3,30963,2)
;;=^5011758
;;^UTILITY(U,$J,358.3,30964,0)
;;=M34.0^^123^1598^13
;;^UTILITY(U,$J,358.3,30964,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30964,1,3,0)
;;=3^Progressive systemic sclerosis
;;^UTILITY(U,$J,358.3,30964,1,4,0)
;;=4^M34.0
;;^UTILITY(U,$J,358.3,30964,2)
;;=^5011778
;;^UTILITY(U,$J,358.3,30965,0)
;;=M31.1^^123^1598^14
;;^UTILITY(U,$J,358.3,30965,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30965,1,3,0)
;;=3^Thrombotic Microangiopathy
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XU 3796 printed Dec 13, 2024@02:17:54 Page 2
IBDEI1XU ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30953,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,30953,1,3,0)
+4 ;;=3^Type 1 DM w/ Diabetic Nephropathy
+5 ;;^UTILITY(U,$J,358.3,30953,1,4,0)
+6 ;;=4^E10.21
+7 ;;^UTILITY(U,$J,358.3,30953,2)
+8 ;;=^5002589
+9 ;;^UTILITY(U,$J,358.3,30954,0)
+10 ;;=E10.22^^123^1598^16
+11 ;;^UTILITY(U,$J,358.3,30954,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,30954,1,3,0)
+14 ;;=3^Type 1 DM w/ Diabetic CKD
+15 ;;^UTILITY(U,$J,358.3,30954,1,4,0)
+16 ;;=4^E10.22
+17 ;;^UTILITY(U,$J,358.3,30954,2)
+18 ;;=^5002590
+19 ;;^UTILITY(U,$J,358.3,30955,0)
+20 ;;=D59.3^^123^1598^3
+21 ;;^UTILITY(U,$J,358.3,30955,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,30955,1,3,0)
+24 ;;=3^Hemolytic-uremic syndrome
+25 ;;^UTILITY(U,$J,358.3,30955,1,4,0)
+26 ;;=4^D59.3
+27 ;;^UTILITY(U,$J,358.3,30955,2)
+28 ;;=^55823
+29 ;;^UTILITY(U,$J,358.3,30956,0)
+30 ;;=D69.0^^123^1598^4
+31 ;;^UTILITY(U,$J,358.3,30956,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,30956,1,3,0)
+34 ;;=3^Henoch-Schoeniein Purpura
+35 ;;^UTILITY(U,$J,358.3,30956,1,4,0)
+36 ;;=4^D69.0
+37 ;;^UTILITY(U,$J,358.3,30956,2)
+38 ;;=^5002365
+39 ;;^UTILITY(U,$J,358.3,30957,0)
+40 ;;=M30.0^^123^1598^12
+41 ;;^UTILITY(U,$J,358.3,30957,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,30957,1,3,0)
+44 ;;=3^Polyarteritis nodosa
+45 ;;^UTILITY(U,$J,358.3,30957,1,4,0)
+46 ;;=4^M30.0
+47 ;;^UTILITY(U,$J,358.3,30957,2)
+48 ;;=^5011738
+49 ;;^UTILITY(U,$J,358.3,30958,0)
+50 ;;=M31.0^^123^1598^5
+51 ;;^UTILITY(U,$J,358.3,30958,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,30958,1,3,0)
+54 ;;=3^Hypersensitivity angiitis
+55 ;;^UTILITY(U,$J,358.3,30958,1,4,0)
+56 ;;=4^M31.0
+57 ;;^UTILITY(U,$J,358.3,30958,2)
+58 ;;=^60279
+59 ;;^UTILITY(U,$J,358.3,30959,0)
+60 ;;=M31.31^^123^1598^22
+61 ;;^UTILITY(U,$J,358.3,30959,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,30959,1,3,0)
+64 ;;=3^Wegener's granulomatosis w/ renal involvement
+65 ;;^UTILITY(U,$J,358.3,30959,1,4,0)
+66 ;;=4^M31.31
+67 ;;^UTILITY(U,$J,358.3,30959,2)
+68 ;;=^5011745
+69 ;;^UTILITY(U,$J,358.3,30960,0)
+70 ;;=N28.89^^123^1598^6
+71 ;;^UTILITY(U,$J,358.3,30960,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,30960,1,3,0)
+74 ;;=3^Kidney & Ureter Disorders,Oth Specified
+75 ;;^UTILITY(U,$J,358.3,30960,1,4,0)
+76 ;;=4^N28.89
+77 ;;^UTILITY(U,$J,358.3,30960,2)
+78 ;;=^88007
+79 ;;^UTILITY(U,$J,358.3,30961,0)
+80 ;;=E85.4^^123^1598^11
+81 ;;^UTILITY(U,$J,358.3,30961,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,30961,1,3,0)
+84 ;;=3^Organ-limited amyloidosis
+85 ;;^UTILITY(U,$J,358.3,30961,1,4,0)
+86 ;;=4^E85.4
+87 ;;^UTILITY(U,$J,358.3,30961,2)
+88 ;;=^5003017
+89 ;;^UTILITY(U,$J,358.3,30962,0)
+90 ;;=M32.14^^123^1598^2
+91 ;;^UTILITY(U,$J,358.3,30962,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,30962,1,3,0)
+94 ;;=3^Glomerular disease in systemic lupus erythematosus
+95 ;;^UTILITY(U,$J,358.3,30962,1,4,0)
+96 ;;=4^M32.14
+97 ;;^UTILITY(U,$J,358.3,30962,2)
+98 ;;=^5011757
+99 ;;^UTILITY(U,$J,358.3,30963,0)
+100 ;;=M32.15^^123^1598^15
+101 ;;^UTILITY(U,$J,358.3,30963,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,30963,1,3,0)
+104 ;;=3^Tubulo-interstitial neuropathy in SLE
+105 ;;^UTILITY(U,$J,358.3,30963,1,4,0)
+106 ;;=4^M32.15
+107 ;;^UTILITY(U,$J,358.3,30963,2)
+108 ;;=^5011758
+109 ;;^UTILITY(U,$J,358.3,30964,0)
+110 ;;=M34.0^^123^1598^13
+111 ;;^UTILITY(U,$J,358.3,30964,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,30964,1,3,0)
+114 ;;=3^Progressive systemic sclerosis
+115 ;;^UTILITY(U,$J,358.3,30964,1,4,0)
+116 ;;=4^M34.0
+117 ;;^UTILITY(U,$J,358.3,30964,2)
+118 ;;=^5011778
+119 ;;^UTILITY(U,$J,358.3,30965,0)
+120 ;;=M31.1^^123^1598^14
+121 ;;^UTILITY(U,$J,358.3,30965,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,30965,1,3,0)
+124 ;;=3^Thrombotic Microangiopathy
